Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study
Authors:
- Paul J. NederkoornPNPaul J. Nederkoorn
- Yolanda van der GraafYGYolanda van der Graaf
- Mirjam I. GeerlingsMGMirjam I. Geerlings
- 1 June 2011
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 216 (2) , 461-466
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trialThe Lancet Neurology, 2010
- Association of plasma homocysteine concentration with cerebral white matter hyperintensity on magnetic resonance images in stroke patientsJournal of the Neurological Sciences, 2009
- Impact of white matter hyperintensity volume progression on rate of cognitive and motor declineNeurology, 2008
- Homocysteine-lowering therapy: a role in stroke prevention?The Lancet Neurology, 2007
- Homocysteine, cerebrovascular disease and brain atrophyJournal of the Neurological Sciences, 2004
- Homocysteine and the Brain in Midadult LifeArchives of Neurology, 2004
- Plasma Total Homocysteine Levels and Cranial Magnetic Resonance Imaging Findings in Elderly PersonsArchives of Neurology, 2004
- Is Breakdown of the Blood-Brain Barrier Responsible for Lacunar Stroke, Leukoaraiosis, and Dementia?Stroke, 2003
- Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosisBrain, 2003
- Cerebral White Matter Lesions, Retinopathy, and Incident Clinical StrokeJAMA, 2002